The Galien Forum USA 2018

PANEL
1

Chair
Robert S. Langer, MD, PhD
David Koch Institute Professor
Massachusetts Institute
of Technology

Panelists

Sarah Akerman, M.D
Senior Medical Director
Alkermes

Patrice A. Harris, MD, MA
President-elect
American Medical Association

Michael Heffernan
Chairman
Collegium Pharmaceutical

Corey McCann, MD, PhD
President and Chief
Executive Officer
Pear Therapeutics

Panel Intro

Novel Approaches to Combatting Opioid Addiction


Robert Langer

Robert S. Langer, MD, PhD
David Koch Institute Professor
Massachusetts Institute of Technology

Robert Langer is an Institute Professor at MIT (there are 13 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member). He has written more than 1,400 articles and has over 1,350 issued and pending patents worldwide.  His many awards include the US National Medal of Science, the US National Medal of Technology and Innovation, the Charles Stark Draper Prize (considered the engineering Nobel Prize), Albany Medical Center Prize (largest US medical prize), the Wolf Prize for Chemistry, the 2014 Kyoto Prize and the Lemelson-MIT prize, for being “one of history’s most prolific inventors in medicine.” Langer is the most cited engineer in history (h index 261)


Sarah Akerman, M.D
Senior Medical Director
Alkermes

Sarah Akerman, MD is a board certified addiction psychiatrist with experience in research and the clinical care of patients with substance use disorders and other psychiatric disorders. Dr. Akerman joined Alkermes in 2016 and currently serves as a Senior Medical Director in the Medical Affairs department. In this position, she oversees the medical strategy and lifecycle management for the company’s addiction therapies, provides expertise to cross-functional partners, and has experience building and strengthening relationships with thought leaders and organizations in the addiction space. Dr. Akerman received a Bachelor of Arts from Tufts University and a Doctor of Medicine from the University Of Miami Miller School Of Medicine. She completed a psychiatry residency and addiction clinical and research fellowships at the Dartmouth Geisel School of Medicine where she then served as a faculty member. She is currently an Adjunct Assistant Professor at the Dartmouth Geisel School of Medicine.


Patrice Harris

Patrice A. Harris, MD, MA
President-elect
American Medical Association

Patrice A. Harris, MD, MA, was elected president–elect of the American Medical Association in June 2018. A psychiatrist from Atlanta, Dr. Harris has diverse experience as a private practicing physician, public health administrator, patient advocate and medical society lobbyist. Active in organized medicine her entire career, Dr. Harris has served on the board of the American Psychiatric Association (APA) and was an APA delegate to the AMA. She has also been a member of the governing council of the AMA Women Physicians Congress, testified before and served on AMA reference committees, and has served on AMA work groups on health information technology, SGR and private contracting.

The AMA Board of Trustees (BOT) appointed her to the AMA Council on Legislation in 2003, and she was elected by the council in 2010 to serve as its chair. She was first elected to the AMA-BOT in June 2011. Dr. Harris has held many leadership positions at the state level as well, including serving on the board and as president of the Georgia Psychiatric Physicians Association and on the Medical Association of Georgia’s Council on Legislation, its Committee on Constitution and Bylaws, and its Membership Task Force. She was also the founding president of the Georgia Psychiatry Political Action Committee. In 2001 Dr. Harris was selected Psychiatrist of the Year by the Georgia Psychiatric Physicians Association. In 2007 she was inducted into the West Virginia University Academy of Distinguished Alumni. Governing themes in Dr. Harris’ professional life are a passion to improve the lives of children and service to others.

Starting with medical school at West Virginia University, followed by a psychiatry residency and child psychiatry and forensics fellowships at Emory, and then as the Barton senior policy fellow at the Emory University School of Law, she has worked for children both clinically and in the advocacy arena. At Emory she addressed public policy for abused and neglected children before the Georgia legislature and in public education programs. Dr. Harris has also given invited lectures and presentations on children’s mental health, childhood trauma, integration of health services, health equity, and the intersection of athletics and health.


Michael Heffernan

Michael Heffernan
Chairman
Collegium Pharmaceutical

Michael Heffernan has over 30 years of experience in the pharmaceutical and related healthcare industries. He is Founder, and is currently the Chairman of Collegium Pharmaceutical (NASDAQ: COLL), a specialty pharmaceutical company focused on responsible pain management including the development of abuse deterrent products for the treatment of chronic pain. He previously served as the CEO of Collegium until June 2018. He was also the founder, President and CEO of Onset Dermatologics, a dermatology focused company that was spun out of Collegium to create PreCision Dermatology and was later sold to Valeant (2014). Michael held prior positions as Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp and later served as President and CEO of PhyMatrix.

Michael began his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been an advisor and Investor in a number of biopharma, medical device and healthcare services companies. His recent board memberships include: TyRx (sold to Medtronic), Cornerstone Therapeutics (sold to Chiesi), PreCision Dermatology (sold to Valeant), and Ocata Therapeutics (sold to Astellas). Michael is currently Chairman of the board of Veloxis Pharmaceuticals (OMX: VELO) and a board member of Keryx Biopharmaceuticals (NASDAQ: KERX) and Trevi Therapeutics. Michael has a B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.


Corey McCann
Corey McCann, MD, PhD
President and Chief Executive Officer
Pear Therapeutics

Corey is a physician, scientist, entrepreneur, and healthcare investor. Previously, he was an investor with MPM Capital and with RiverVest Venture Partners, where he evaluated new investment opportunities, managed relationships with strategic partners, and oversaw board-level strategy and execution at portfolio companies. Prior to MPM, he was with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He also led McKinsey’s Central Nervous System (CNS) expertise group, serving clients across pharma and biotech. He is a founding member of multiple start-ups including Alcyone Lifesciences, a company developing technologies to deliver therapeutics to the brain

Dr. McCann’s post-graduate training was at Harvard University, Washington University in St Louis, and at the Massachusetts General Hospital, and he graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar.